Virax Biolabs Group Analyst Price Targets - Benzinga

Virax Biolabs Group Ltd

VRAXNASDAQ

Trade with Public

Trade with Public

$1.29

0.097.5%

마지막 업데이트: Oct 29, 9:29 AM

개요 뉴스 이벤트목표가재무 심리 비교 주식 보고서

Virax Biolabs Group Analyst Price Targets

Wall Street analyst price targets and consensus rating for Virax Biolabs Group (VRAX).

Price Target Range — 2 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$25Upside to Avg. PT+1838.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jan 9, 2026	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$75→$25
Mar 31, 2025	HC Wainwright & Co.	Yi Chen	Initiate	Buy	$75

Analyst Ratings News

Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.

Vandana Singh

PRO
HC Wainwright & Co. Initiates Coverage On Virax Biolabs Group with Buy Rating, Announces Price Target of $3

HC Wainwright & Co. analyst Yi Chen initiates coverage on Virax Biolabs Group (NASDAQ:VRAX) with a Buy rating and announces Price Target of $3.

Benzinga Newsdesk